We could not be more proud that Yasmin Hasan has been named UChicago Program Director of the Year! #GME #MedEd #RadOnc #Residency #Match UChicago GME

Our review titled: SBRT for Liver Tumors: What the Interventional Radiologist Needs to Know, is out now! Many thanks to my talented colleagues Rohan Katipally, Michael Gutman, and Dr. Koshy. Link: thieme-connect.com/products/ejour…

Happy #matchday2024! We are thrilled to introduce our Class of 2029: Farris Jaamour, Mira Patel, and Montserrat Quintana! #RadOnc #GME UChicago Medicine #match2024

My honour to meet the legendary Ralph Weichselbaum in the flesh! He gave a fascinating impromptu lecture on oligometastases; take homes 1) clinical risk (volume, rate of recurrences, imaging) 2) molecular risk and 3) total metastatic ablation are all important! #radonc the Radiosurgery Society

A new 🌟 TARPSWG achievement: solid data on the largest series of WDLPS #retroperitoneal #sarcoma: after Neoadjuvant RT significantly reduced local recurrence rate Vs surgery alone. #STRASS and #STREXIT data are now corroborated. Great job Mark Fairweather! #SSO2024 #plenary

Thank you Grey's Anatomy for highlighting our COSINR trial at UChicagoCancerCenter University of Chicago Radiation Oncology for cytoreductive ablative radiotherapy and immunotherapy for first-line metastatic NSCLC.

📰 Excellent review article on recent advances in understanding the immune system activation with radiotherapy to induce anti-tumor effects and benefit of combination Rxs in controlling tumor growth. University of Chicago Radiation Oncology Journal of Experimental Medicine Sean Pitroda, M.D. Ludwig Cancer ow.ly/M1Zc50RRtby

🚨NEW CASE ALERT!🚨 Aranee Sivananthan from University of Chicago Radiation Oncology submitted a 🌟prostate case with an MRI-delineated DIL boost! econtour.org/cases/163 Just look at that nodule and that urethra! PS: brush up on your MRI knowledge as we discuss tumor signal intensity on T2 & ADC series!

Check out our multi-center phase 2 IIT currently accruing for upfront SBRT added to Durvalumab-based chemoimmunotherapy for the first line treatment of extensive stage SCLC - the DARES trial. Christine Bestvina Docace911 clinical-lung-cancer.com/article/S1525-…

Very honored to be representing uchicago with such a great group of colleagues at this year’s Latino Medical Student Association conference. All the interested medical students + undergrads were stellar! 🤩 UChicago GME UChicago Medicine UChicagoCancerCenter University of Chicago Radiation Oncology LMSA National

Check out the latest from UChicagoCancerCenter HN Group - the DEPEND trial. 1) There is strong interest in determining how to incorporate immunotherapy into non-operative management for LA-HNSCC to improve outcomes for high risk HPV-negative patients.

Growing up, dinner was more than just a meal—it was a space for debate and a deeper understanding of our country’s most pressing issues. I learned about American heroes like my grandfather, who dedicated his life to ensuring that families in Indianapolis (continued below)

We are thrilled to announce our newly-matched 2030 class of radiation oncology residents: Chad Caraway, Alexander Cooke, and Azan Haque. Welcome! Azan Haque

Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Prior to Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer: brnw.ch/21wRHpX Authored by Aditya Juloori et al. #NSCLC #lcsm

Congrats to our incoming Chief Resident John White for his EAGL honors!

Had the opportunity of a lifetime to meet with fellow veteran, Hoosier and former Secretary of Transportation Pete Buttigieg. While the conversation was off the record, I was struck by how thoughtful, kind, and genuinely committed he is to making our country better.Pete Buttigieg

#April is National Cancer Control Month Cigarette smoking remains the #1 risk factor for lung cancer. Low-dose CT scans can detect it early for high-risk individuals—allowing for life-saving intervention. Learn more about lung cancer screening: ow.ly/7GW350VyZse

Terrific visit today from UMich Rad Onc 's Dr. Ted Lawrence, pictured here with our Rad Onc residents.

We are grateful for the tremendous response to our recent manuscript and want to ensure a precise interpretation of our findings. Our research indicates that local radiation therapy in patients with pre-existing metastases may exert paradoxical effects—reducing the dissemination

🧵1/ Tumor aneuploidy—long viewed as a hallmark of cancer—is emerging as a key biomarker of immune resistance. In our latest Nature Genetics Perspective, we explore how aneuploidy can guide immunotherapy decisions and shape future treatment strategies. 🔗 doi.org/10.1038/s41588…